Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.

Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'connor DT.

Clin Pharmacol Ther. 2004 Aug;76(2):139-53.

PMID:
15289791
2.
3.

The catecholamine release-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of hypertension.

O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ.

Ann N Y Acad Sci. 2002 Oct;971:533-5. No abstract available.

PMID:
12438176
4.

Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.

O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ.

J Hypertens. 2002 Jul;20(7):1335-45.

PMID:
12131530
5.

Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences.

O'Connor DT, Tyrell EA, Kailasam MT, Miller LM, Martinez JA, Henry RR, Parmer RJ, Gabbai FB.

Hypertension. 2001 Mar;37(3):898-906.

PMID:
11244015
6.

Chromogranin A in human disease.

O'Connor DT, Mahata SK, Taupenot L, Mahata M, Livsey Taylor CV, Kailasam MT, Ziegler MG, Parmer RJ.

Adv Exp Med Biol. 2000;482:377-88. Review. No abstract available.

PMID:
11192598
7.

Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity.

Lacy F, Kailasam MT, O'Connor DT, Schmid-Schönbein GW, Parmer RJ.

Hypertension. 2000 Nov;36(5):878-84.

PMID:
11082160
8.

Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.

Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT.

J Hypertens. 2000 Nov;18(11):1611-20.

PMID:
11081774
9.

Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans.

Herrmann V, Büscher R, Go MM, Ring KM, Hofer JK, Kailasam MT, O'Connor DT, Parmer RJ, Insel PA.

Am J Hypertens. 2000 Sep;13(9):1021-6.

PMID:
10981553
10.

Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension.

Song CK, Martinez JA, Kailasam MT, Dao TT, Wong CM, Parmer RJ, O'Connor DT.

J Hum Hypertens. 2000 Jul;14(7):461-8.

11.

Variability in phenylephrine response and essential hypertension: a search for human alpha(1B)-adrenergic receptor polymorphisms.

Büscher R, Herrmann V, Ring KM, Kailasam MT, O'Connor DT, Parmer RJ, Insel PA.

J Pharmacol Exp Ther. 1999 Nov;291(2):793-8.

PMID:
10525102
12.

Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.

Kailasam MT, Martinez JA, Cervenka JH, Yen SS, O'connor DT, Parmer RJ.

Kidney Int. 1998 Nov;54(5):1652-8.

13.

Expression of altered alpha2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension.

Dao TT, Kailasam MT, Parmer RJ, Le HV, Le Verge R, Kennedy BP, Ziegler G, Insel PA, Wright FA, O'Connor DT.

J Hypertens. 1998 Jun;16(6):779-92.

PMID:
9663918
14.

Development and validation of a noninvasive method to determine arterial pressure and vascular compliance.

Brinton TJ, Cotter B, Kailasam MT, Brown DL, Chio SS, O'Connor DT, DeMaria AN.

Am J Cardiol. 1997 Aug 1;80(3):323-30.

PMID:
9264426
15.

Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk.

Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio SS, Parmer RJ, DeMaria AN, O'Connor DT.

Hypertension. 1996 Oct;28(4):599-603.

PMID:
8843884
16.

Hereditary intermediate phenotypes in African American hypertension.

Kailasam MT, O'Connor DT, Parmer RJ.

Ethn Health. 1996 May;1(2):117-28. Review.

PMID:
9395555
17.

Complex trait genetics: new methods yield a result for essential hypertension.

O'Connor DT, Kailasam MT, Parmer RJ.

J Clin Invest. 1996 May 1;97(9):1997-8. No abstract available.

18.

Chromogranin A in human hypertension. Influence of heredity.

Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, et al.

Hypertension. 1995 Jul;26(1):213-20.

PMID:
7607727
19.

Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension.

Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP, Adegbile IA, O'Connor DT.

Hypertension. 1995 Jul;26(1):143-9.

PMID:
7607717
20.

Factitious pheochromocytoma: novel mimickry by Valsalva maneuver and clues to diagnosis.

Kailasam MT, Parmer RJ, Stone RA, Shankel S, Kennedy BP, Ziegler MG, O'Connor DT.

Am J Hypertens. 1995 Jun;8(6):651-5.

PMID:
7662252
21.

Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension?

Wu RA, Kailasam MT, Cervenka JH, Parmer RJ, Kennedy BP, Ziegler MG, O'Connor DT.

J Hypertens. 1994 Nov;12(11):1243-7.

PMID:
7868871
22.

Effects of an oral prostaglandin E1 agonist on blood pressure and its determinants in essential hypertension.

Kailasam MT, Lin MC, Cervenka JH, Parmer RJ, Kennedy BP, Ziegler MG, O'Connor DT.

J Hum Hypertens. 1994 Jul;8(7):515-20.

PMID:
7932515
23.

Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia.

O'Connor DT, Kailasam MT, Thal LJ.

Neurobiol Aging. 1993 May-Jun;14(3):267-9.

PMID:
8321395

Supplemental Content

Loading ...
Support Center